Navelbine (Vinorelbine Tartrate)

Navelbine is a chemotherapy agent used in the management of solid tumours that rely on microtubule inhibition.

• Non‑small cell lung cancer: improves disease control and overall survival when combined with standard regimens.
• Metastatic breast cancer: provides tumour reduction and symptom relief in patients with prior therapy.
• Advanced or recurrent solid tumours: may be considered as part of combination protocols when other options are limited.

• Vinorelbine binds to tubulin at the Vinca binding site, preventing microtubule polymerisation. This disrupts the mitotic spindle, causing cell‑cycle arrest in the M phase and ultimately triggering apoptosis of rapidly dividing cancer cells. The drug’s activity is independent of DNA synthesis and is selective for proliferating tumour cells.

Vinorelbine is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Anemia: decreased red blood cells causing fatigue.
• Nausea and vomiting: gastrointestinal upset common after oral dosing.
• Constipation: bowel motility reduction.
• Fatigue: generalised tiredness.
• Alopecia: hair thinning or loss.

Serious or Rare Side Effects

• Severe neutropenia with febrile infection.
• Pulmonary toxicity, including interstitial pneumonitis.
• Peripheral neuropathy: tingling or numbness in extremities.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms.
• Hepatic dysfunction: elevated liver enzymes or jaundice.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients closely.

• Monitor blood counts: perform regular complete blood counts to detect myelosuppression.
• Assess liver function: check hepatic enzymes and bilirubin prior to each cycle.
• Evaluate pulmonary status: avoid use in patients with pre‑existing severe lung disease.
• Use caution in the elderly: dose adjustments may be required due to reduced clearance.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Vinorelbine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinorelbine exposure.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce therapeutic levels.
• Concurrent myelosuppressive chemotherapy: markedly heighten bone‑marrow toxicity.

Moderate Interactions (Monitor Closely)

• Antiemetics such as ondansetron: may affect QT interval.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters.
• Diuretics: watch for electrolyte disturbances.
• CYP2D6 substrates: potential modest effect on metabolism.